Labcorp Holdings Inc (LH) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Labcorp Holdings Inc   (NYSE: LH)
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare

Select the Financial Report: Select the Period:


Description of Labcorp Holdings Inc's Business Segments


Labcorp Holdings Inc. is a major global player in the life sciences sector, predominantly recognized for its comprehensive medical laboratory services, diagnostic testing, and drug development offerings. The companys operations are primarily encapsulated within one principal segment, Labcorp Diagnostics, which delivers a broad spectrum of critical healthcare services catering to healthcare providers, pharmaceutical firms, and research organizations.

1. Labcorp Diagnostics

The Labcorp Diagnostics segment is the cornerstone of the company’s operations. It emphasizes high-quality laboratory services and diagnostic testing services across various medical disciplines. The offerings in this segment can be categorized into the following key areas:

a. Clinical Laboratory Services

Labcorp’s clinical laboratory services are extensive, supporting healthcare professionals in the diagnosis, monitoring, and management of various medical conditions. The services can be further broken down into:

- Routine Testing: This includes general laboratory tests, such as blood tests, urinalysis, and other common diagnostic procedures that are essential in routine medical examinations.

- Specialty Testing: Labcorp offers advanced diagnostic tests spanning diverse medical fields such as endocrinology, toxicology, cardiology, and infectious diseases, catering to more complex patient needs.

- Genetic Testing: A comprehensive suite of genetic testing services is available, including:
- Carrier Screening for inherited genetic conditions.
- Hereditary Cancer Testing to assess risks for certain types of cancers.
- Pharmacogenomics to predict how patients will respond to medications based on their genetic makeup.
- Prenatal Testing to evaluate the health of the fetus during pregnancy.

- Pathology Services: Labcorp provides a wide range of pathology services, which include:
- Anatomic Pathology: Involves the examination of tissues and cells to diagnose diseases.
- Histology and Cytology: Specialized tests focusing on microscopic examination of tissues and cellular material.
- Molecular Pathology: Advanced techniques to analyze genetic material for diagnostics.

b. Point-of-Care Testing

Labcorp extends its services to include point-of-care testing solutions, creating convenience for healthcare providers and patients. These offerings consist of:

- Rapid Diagnostic Tests: These tests, which can be conducted quickly, include diagnostics for conditions such as COVID-19, influenza, strep throat, and pregnancy.

- Home Health Testing: This service allows patients to conveniently collect samples at home for various tests, improving access to healthcare.

c. Patient Services

Enhancing the patient experience is a priority for Labcorp, which provides a variety of patient services, including:

- Lab Locations: A vast network of patient service centers is available for individuals to access convenient testing options.

- Mobile Health Solutions: Offerings for at-home sample collection cater to patients who may have difficulty visiting traditional lab settings.

Drug Development Services

Complementing its diagnostics portfolio, Labcorp plays a significant role in drug development through its Labcorp Drug Development segment. This branch is integral for pharmaceutical and biotechnology companies involved in the journey to develop new drugs. Key offerings include:

a. Preclinical and Clinical Development

Labcorp provides a wide array of services throughout the drug development lifecycle:

- Preclinical Services: This consists of both in vitro (test tube experiments) and in vivo (animal studies) assessments to gauge the safety and efficacy of new compounds.

- Clinical Trials: The company manages clinical trials at all phases (Phase I to IV), offering extensive support that includes study design, patient recruitment, monitoring, and data analysis.

b. Central Laboratory Services

Labcorp maintains central laboratories that provide laboratory testing specifically for clinical trials, including:

- Sample Management: This encompasses logistics, processing, and tracking of samples obtained from trial sites.

- Data Management: Leveraging advanced data analytics to ensure precise reporting and compliance with regulatory standards.

c. Regulatory and Consultation Services

Navigating the complex regulatory landscape of drug development can be challenging, and Labcorp offers valuable consultation and advisory services:

- Regulatory Affairs: Providing guidance on submissions and interactions with regulatory agencies, including the FDA.

- Scientific & Statistical Services: Delivering expertise in biostatistics, data management, and clinical analytics to support drug development projects.

Specialized Areas

Labcorp emphasizes specialized testing to augment its service offerings, notably in:

a. Women’s Health

A focused suite of testing services designed for womens health issues, including reproductive health and prenatal testing options.

b. Oncology

Targeted testing services tailored for cancer diagnostics and monitoring. This includes innovative techniques such as liquid biopsies and tumor profiling to inform treatment decisions.

c. Infectious Disease

Comprehensive testing services for a wide array of infectious diseases are provided, including HIV, hepatitis, and a range of emerging pathogens, which are vital in surveillance and management of public health.

Innovation and Technology

Labcorp is committed to integrating innovative technology within its operations to enhance service delivery:

- Digital Solutions: Platforms that promote patient engagement, facilitate telemedicine consultations, and streamline electronic test ordering.

- Laboratory Automation: Employing automated systems to improve testing efficiency, accuracy, and throughput in laboratory operations.

Conclusion

Labcorp Holdings Inc. represents a leader in laboratory diagnostics and drug development services, with a rich and diverse array of testing capabilities. Through its unwavering commitment to high-quality diagnostics, patient service innovation, and an array of specialized offerings, Labcorp plays a critical role in driving healthcare advancements and supporting the pharmaceutical industry in drug development endeavors. This broad and integrated approach illustrates Labcorps mission to enhance health outcomes and improve lives on a global scale.


Composition of Labcorp Holdings Inc Revenues by Segments

 
North America    0 % of total Revenue
Europe    0 % of total Revenue
Other countries    0 % of total Revenue
UNITED STATES    82.37 % of total Revenue
Diagnostics    78.08 % of total Revenue
Diagnostics North America    0 % of total Revenue
Diagnostics Client    0 % of total Revenue
Diagnostics Client North America    0 % of total Revenue
Diagnostics Self-Pay    0 % of total Revenue
Diagnostics Self-Pay North America    0 % of total Revenue
Diagnostics Medicare and Medicaid    0 % of total Revenue
Diagnostics Medicare and Medicaid North America    0 % of total Revenue
Diagnostics Third party    0 % of total Revenue
Diagnostics Third party North America    0 % of total Revenue
Biopharma Laboratory Services    22.07 % of total Revenue
Biopharma Laboratory Services Biopharmaceutical and medical device companies    0 % of total Revenue
Biopharma Laboratory Services Biopharmaceutical and medical device companies North America    0 % of total Revenue
Biopharma Laboratory Services Biopharmaceutical and medical device companies Europe    0 % of total Revenue
Biopharma Laboratory Services Biopharmaceutical and medical device companies Other countries    0 % of total Revenue
InterEliminations    0.14 % of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
North America 0.00 0 %
Europe 0.00 0 %
Other countries 0.00 0 %
UNITED STATES 2,914.00 82.37 %
Diagnostics 2,762.10 78.08 %
Diagnostics North America 0.00 0 %
Diagnostics Client 0.00 0 %
Diagnostics Client North America 0.00 0 %
Diagnostics Self-Pay 0.00 0 %
Diagnostics Self-Pay North America 0.00 0 %
Diagnostics Medicare and Medicaid 0.00 0 %
Diagnostics Medicare and Medicaid North America 0.00 0 %
Diagnostics Third party 0.00 0 %
Diagnostics Third party North America 0.00 0 %
Biopharma Laboratory Services 780.60 22.07 %
Biopharma Laboratory Services Biopharmaceutical and medical device companies 0.00 0 %
Biopharma Laboratory Services Biopharmaceutical and medical device companies North America 0.00 0 %
Biopharma Laboratory Services Biopharmaceutical and medical device companies Europe 0.00 0 %
Biopharma Laboratory Services Biopharmaceutical and medical device companies Other countries 0.00 0 %
InterEliminations 5.10 0.14 %
Total 3,537.60 100 %




Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
North America -1.15 % -
Europe 11.11 % -
Other countries 0 % -
UNITED STATES 3.56 % -
Diagnostics 5.04 % -
Diagnostics North America 0 % -
Diagnostics Client -4.17 % -
Diagnostics Client North America -4.17 % -
Diagnostics Self-Pay 0 % -
Diagnostics Self-Pay North America 0 % -
Diagnostics Medicare and Medicaid 0 % -
Diagnostics Medicare and Medicaid North America 0 % -
Diagnostics Third party 2.78 % -
Diagnostics Third party North America 2.78 % -
Biopharma Laboratory Services 8.22 % -
Biopharma Laboratory Services Biopharmaceutical and medical device companies 0 % -
Biopharma Laboratory Services Biopharmaceutical and medical device companies North America -11.11 % -
Biopharma Laboratory Services Biopharmaceutical and medical device companies Europe 11.11 % -
Biopharma Laboratory Services Biopharmaceutical and medical device companies Other countries 0 % -
InterEliminations -12.07 % -
Total 5.75 % -




Q1 three months ended (Mar 31 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Diagnostics 458.70 16.61 %
Biopharma Laboratory Services 120.70 15.46 %
Total 278.00 7.86 %




Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Diagnostics 7.3 % -
Biopharma Laboratory Services 12.91 % -
Total 30.52 % -




Annual Report on Labcorp Holdings Inc Divisions, Sales by Country

 
North America   North America Segment contribution to total sales 0 % of total Revenue
Europe   Europe Segment contribution to total sales 0 % of total Revenue
Other countries   Other countries Segment contribution to total sales 0 % of total Revenue
Diagnostics   Diagnostics Segment contribution to total sales 77.96 % of total Revenue
Diagnostics North America   Diagnostics North America Segment contribution to total sales 0 % of total Revenue
Diagnostics Medicare and Medicaid   Diagnostics Medicare and Medicaid Segment contribution to total sales 0 % of total Revenue
Diagnostics Third party   Diagnostics Third party Segment contribution to total sales 0 % of total Revenue
Biopharma Laboratory Services   Biopharma Laboratory Services Segment contribution to total sales 22.21 % of total Revenue
InterEliminations   InterEliminations Segment contribution to total sales 0.16 % of total Revenue
Geographic Distribution Domestic   Geographic Distribution Domestic Segment contribution to total sales 83.5 % of total Revenue
Diagnostics Patients   Diagnostics Patients Segment contribution to total sales 0 % of total Revenue
Diagnostics Clients   Diagnostics Clients Segment contribution to total sales 0 % of total Revenue
Diagnostics North America Third party   Diagnostics North America Third party Segment contribution to total sales 0 % of total Revenue
Diagnostics North America Medicare and Medicaid   Diagnostics North America Medicare and Medicaid Segment contribution to total sales 0 % of total Revenue
Diagnostics North America Patients   Diagnostics North America Patients Segment contribution to total sales 0 % of total Revenue
Diagnostics North America Clients   Diagnostics North America Clients Segment contribution to total sales 0 % of total Revenue
Biopharma Laboratory Services Pharmaceutical biotechnology medical device and diagnostic companies and CROs   Biopharma Laboratory Services Pharmaceutical biotechnology medical device and diagnostic companies and CROs Segment contribution to total sales 0 % of total Revenue
Biopharma Laboratory Services Europe Pharmaceutical biotechnology medical device and diagnostic companies and CROs   Biopharma Laboratory Services Europe Pharmaceutical biotechnology medical device and diagnostic companies and CROs Segment contribution to total sales 0 % of total Revenue
Biopharma Laboratory Services North America Pharmaceutical biotechnology medical device and diagnostic companies and CROs   Biopharma Laboratory Services North America Pharmaceutical biotechnology medical device and diagnostic companies and CROs Segment contribution to total sales 0 % of total Revenue
Biopharma Laboratory Services Other countries Pharmaceutical biotechnology medical device and diagnostic companies and CROs   Biopharma Laboratory Services Other countries Pharmaceutical biotechnology medical device and diagnostic companies and CROs Segment contribution to total sales 0 % of total Revenue


Twelve months ended 2025
LH s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
North America 0.00 0 %
Europe 0.00 0 %
Other countries 0.00 0 %
Diagnostics 10,876.50 77.96 %
Diagnostics North America 0.00 0 %
Diagnostics Medicare and Medicaid 0.00 0 %
Diagnostics Third party 0.00 0 %
Biopharma Laboratory Services 3,098.20 22.21 %
InterEliminations 23.00 0.16 %
Total 13,951.70 100 %
Geographic Distribution Domestic 11,650.10 83.5 %
Diagnostics Patients 0.00 0 %
Diagnostics Clients 0.00 0 %
Diagnostics North America Third party 0.00 0 %
Diagnostics North America Medicare and Medicaid 0.00 0 %
Diagnostics North America Patients 0.00 0 %
Diagnostics North America Clients 0.00 0 %
Biopharma Laboratory Services Pharmaceutical biotechnology medical device and diagnostic companies and CROs 0.00 0 %
Biopharma Laboratory Services Europe Pharmaceutical biotechnology medical device and diagnostic companies and CROs 0.00 0 %
Biopharma Laboratory Services North America Pharmaceutical biotechnology medical device and diagnostic companies and CROs 0.00 0 %
Biopharma Laboratory Services Other countries Pharmaceutical biotechnology medical device and diagnostic companies and CROs 0.00 0 %


Twelve months ended 2025
LH s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total 877.70 6.29 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
North America 0 % -
Europe 0 % -
Other countries 0 % -
Diagnostics 7.22 % -
Diagnostics North America 0 % -
Diagnostics Medicare and Medicaid 0 % -
Diagnostics Third party 2.78 % -
Biopharma Laboratory Services 6.01 % -
InterEliminations -60.34 % -
Total 7.25 % 17.48 %
Geographic Distribution Domestic 7.29 % -
Diagnostics Patients 0 % -
Diagnostics Clients -4.17 % -
Diagnostics North America Third party 2.78 % -
Diagnostics North America Medicare and Medicaid 0 % -
Diagnostics North America Patients 0 % -
Diagnostics North America Clients -4.17 % -
Biopharma Laboratory Services Pharmaceutical biotechnology medical device and diagnostic companies and CROs 0 % -
Biopharma Laboratory Services Europe Pharmaceutical biotechnology medical device and diagnostic companies and CROs 0 % -
Biopharma Laboratory Services North America Pharmaceutical biotechnology medical device and diagnostic companies and CROs 0 % -
Biopharma Laboratory Services Other countries Pharmaceutical biotechnology medical device and diagnostic companies and CROs 0 % -
LabCorp Diagnostics - -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.